Business news from Ukraine

Business news from Ukraine

BIOPHARMA PHARMACEUTICAL COMPANY ENCOURAGES COVID-19 SURVIVORS TO DONATE PLASMA

12 May , 2020  

Biopharma pharmaceutical company (Kyiv) urges citizens who came through coronavirus (COVID-19) to become plasma donors to develop a medicine against this disease, which the company is launching. The company told Interfax-Ukraine that hyperimmune immunoglobulin may be effective for specific treatment of COVID-19.
The development of the medicine is carried out under Biopharma’s participation in the work of the International alliance of companies specializing in the production of blood plasma medicines, which also includes Takeda and CSL, Octapharma, Biotest, BPL, LFB, Sanquin, GreenCros, ADMA Biologics.
“Our plasma centers in Sumy, Cherkasy, Dnipro, Kharkiv began plasma blank. All the facilities of our plant in Bila Tserkva, all the forces of our team are directed to the development of medicines. I am sure that effective treatment of COVID-19 will appear,” co-owner of the company Kostiantyn Yefymenko wrote on Facebook.
In turn, businessman Vasyl Khmelnytsky, a co-owner of Biopharma as well, said that the development of an effective medicine against COVID-19 requires the support of people around the world who are ready to donate their plasma after coming through the disease.
“We urge those who have recovered to contribute to the fight against the pandemic and, if their health allows, to become a donor,” he wrote on Facebook.
The company said that Biopharma urged all survivors who wish to become blood plasma donors to contact the company’s hotline. Donors will be transported to their plasma centers, where blood plasma can be donated, and back, and they will get compensation for donation.
The company said that it is ready to register and transfer donors from any settlements.
In addition, Biopharma said that one more direction of the fight against coronavirus infection is the clinical study that have begun to evaluate the effectiveness of Bioven medicine manufactured by Biopharma Plazma LLC in the complex treatment of patients with pneumonia caused by COVID-19 and SARS- CoV-2 coronavirus infection.

, ,